Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-18T03:22:08.727Z Has data issue: false hasContentIssue false
  • English
  • Français

Incidence and Outcomes of Ventilator-Associated Pneumonia in Japanese Intensive Care Units: The Japanese Nosocomial Infection Surveillance System

Published online by Cambridge University Press:  02 January 2015

Machi Suka ,
Katsumi Yoshida ,
Hideo Uno  and
Jun Takezawa
Machi Suka*
Affiliation:
Department of Preventive Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Katsumi Yoshida
Affiliation:
Department of Preventive Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Hideo Uno
Affiliation:
Department of Emergency and Intensive Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Jun Takezawa
Affiliation:
Department of Emergency and Intensive Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
*
Department of Preventive Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan (suka@marianna-u.ac.jp)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives.

To determine the incidence of ventilator-associated pneumonia (VAP) among intensive care unit (ICU) patients in Japan and to assess the impact of VAP on patient outcomes, including mortality, length of stay, and duration of mechanical ventilation.

Design.

Multicenter cohort study.

Setting.

Twenty-eight ICUs in multidisciplinary Japanese hospitals with more than 200 beds.

Patients.

A total of 21,909 patients 16 years or older who were admitted to an ICU between June 2002 and June 2004, stayed in the ICU for 24 to 1,000 hours, and were not transferred to another ICU.

Results.

The overall infection rates for nosocomial pneumonia and VAP were 6.5 cases per 1,000 patient-days and 12.6 cases per 1,000 ventilator-days, respectively. The standardized mortality rates for the patients with VAP was 1.3 (95% confidence interval [CI], 1.1-1.6): 1.1 (95% CI, 0.9-1.4) for the cases due to drug-susceptible pathogens and 1.5 (95% CI, 1.1-1.9) for the cases due to drug-resistant pathogens. After adjusting for Acute Physiology and Chronic Health Evaluation II score, the mean length of stay for the patients with VAP caused by drug-susceptible pathogens (15.2 days [95% CI, 14.6-15.8]) and by drug-resistant pathogens (17.8 days [95% CI, 17.0-18.6]) was significantly longer than that in the patients without nosocomial infection (6.8 days [95% CI, 6.7-6.9]). The mean duration of mechanical ventilation in the patients with VAP caused by drug-susceptible pathogens (12.0 days [95% CI, 11.5-12.5]) and drug-resistant pathogens (14.1 days [95% CI, 13.5-14.8]) was significantly longer than that in the patients without nosocomial infection (4.7 days [95% CI, 4.6-4:8]).

Conclusion.

The incidence of VAP is substantial among ICU patients in Japan. The potential impact of VAP on patient outcomes emphasizes the importance of preventive measures against VAP, especially for VAP caused by drug-resistant pathogens.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 3 , March 2007 , pp. 307 - 313
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Fridkin, SK, Welbel, SF, Weinstein, RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1997;11:479–496.Google Scholar
2.Eggimann, P, Pittet, D. Infection control in the ICU. Chest 2001;120:2059–2093.Google Scholar
3.Chastre, J, Fagon, J-Y. Ventilaor-associated pneumonia. Am J Resp Crit Care Med 2002;165:867–903.Google Scholar
4.Rello, J, Diaz, E. Pneumonia in the intensive care unit. Crit Care Med 2003;31:2544–2551.Google Scholar
5.Rello, J, Ollendorf, DA, Oster, G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115–2121.Google Scholar
6.Cook, D. Ventilator associated pneumonia: perspectives on the burden of illness. Intensive Care Med 2000;26 Suppl 1:S31–S37.Google Scholar
7.Sakakibara, Y, Takezawa, J. Report of the lapan Nosocomial Infection Surveillance, ICU division [in Japanese]. Infect Control 2002;11:530–536.Google Scholar
8.Furuya, N, Yamaguchi, K. Report of the Japan Nosocomial Infection Surveillance, Laboratory division [in Japanese]. Infect Control 2002;11:538–543.Google Scholar
9.Manabe, K, Miyazaki, H, Kawano, F, et al. Report of the Japan Nosocomial Infection Surveillance, Hospitalwide division [in Japanese]. Infect Control 2002;11:546–550.Google Scholar
10.Knaus, WA, Draper, EA, Wagner, DP, Zimmerman, JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–829.CrossRefGoogle ScholarPubMed
11.Garner, JS, Jarvis, WR, Emori, TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.CrossRefGoogle ScholarPubMed
12.Jarvis, WR, Edwards, JR, Culver, DH, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States: National Nosocomial Infections Surveillance System. Am J Med 1991;91:185S–191S.Google Scholar
13.Cook, DJ, Walter, SD, Cook, RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433–440.Google Scholar
14.Gastmeier, P, Schumacher, M, Daschner, F, Ruden, H. An analysis of two prevalence surveys of nosocomial infection in German intensive care units. J Hosp Infect 1997;35:97–105.Google Scholar
15.Legras, A, Malvy, D, Quinioux, AI, et al. Nosocomial infections: prospective survey of incidence in five French intensive care units. Intensive Care Med 1998;24:1040–1046.Google Scholar
16.Richards, MJ, Edwards, R, Culver, DH, Gaynes, RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000;21:510–515.Google Scholar
17.National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–485.Google Scholar
18.Niederman, MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001;29(Suppl):N114–N120.Google Scholar
19.Koeman, M, Bonten, MJM. When can empiric therapy for intensive care unit-acquired pneumonia be withheld or withdrawn? Semin Respir Infect 2003;18:122–128.Google Scholar
20.Mehta, RM, Niederman, MS. Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med 2003;18:175–188.Google Scholar
21.Shlaes, DM, Gerding, DN, John, JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584–599.Google Scholar
22.Albrich, WC, Angstwurm, M, Bader, L, Gartner, R. Drug resistance in intensive care units. Infection 1999;27(Suppl 2):S19–S23Google Scholar
23.Kollef, MH, Fraser, VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134:298–314.Google Scholar
24.Suka, M, Yoshida, K, Takezawa, J. Organizational characteristics of intensive care units related to nosocomial infections: a multicenter study [in Japanese]. Kankyo Kausen 2005;20:24–30.Google Scholar
25.Heyland, DK, Cook, DJ, Griffith, L, et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient: the Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249–1256.Google Scholar
26.Morehead, RS, Pinto, SJ. Ventilator-associated pneumonia. Arch Intern Med 2000;160:1926–1936.Google Scholar
27.Liberati, A, DAmico, R, Pifferi, S, et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2004;1:CD000022.Google Scholar
28.Guidelines for preventing healthcare-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1–36.Google Scholar
29.Dodek, P, Keenan, S, Cook, D, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004;141:305–313.Google Scholar
30.Vincent, JL. Microbial resistance: lessons from the EPIC study. Intensive Care Med 2000;26:S3–S8.Google Scholar